Surface expression of pTα predicts LCK activation, dependency on pre-TCR signaling, and clinical sensitivity to the TKI dasatinib in cortical phenotype T-ALL. In aberrantly pre-TCR and IL-7R coexpressing T-ALL, coinhibition of the IL-7R pathway via the JAK pathway inhibitor ruxolitinib provides therapeutic synergy.

Surface expression of pTα predicts LCK activation, dependency on pre-TCR signaling, and clinical sensitivity to the TKI dasatinib in cortical phenotype T-ALL. In aberrantly pre-TCR and IL-7R coexpressing T-ALL, coinhibition of the IL-7R pathway via the JAK pathway inhibitor ruxolitinib provides therapeutic synergy.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal